- Home
- EWTX vs PD Comparison
EWTX vs PD Comparison
Compare EWTX & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- PD
- Stock Information
- Founded
- EWTX 2017
- PD 2009
- Country
- EWTX United States
- PD United States
- Employees
- EWTX N/A
- PD N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- PD Computer Software: Prepackaged Software
- Sector
- EWTX Health Care
- PD Technology
- Exchange
- EWTX Nasdaq
- PD Nasdaq
- Market Cap
- EWTX 1.6B
- PD 1.5B
- IPO Year
- EWTX 2021
- PD 2019
- Fundamental
- Price
- EWTX $14.95
- PD $15.67
- Analyst Decision
- EWTX Buy
- PD Hold
- Analyst Count
- EWTX 10
- PD 9
- Target Price
- EWTX $37.90
- PD $18.33
- AVG Volume (30 Days)
- EWTX 957.0K
- PD 1.8M
- Earning Date
- EWTX 11-06-2025
- PD 11-25-2025
- Dividend Yield
- EWTX N/A
- PD N/A
- EPS Growth
- EWTX N/A
- PD N/A
- EPS
- EWTX N/A
- PD N/A
- Revenue
- EWTX N/A
- PD $483,608,000.00
- Revenue This Year
- EWTX N/A
- PD $9.16
- Revenue Next Year
- EWTX N/A
- PD $6.79
- P/E Ratio
- EWTX N/A
- PD N/A
- Revenue Growth
- EWTX N/A
- PD 8.20
- 52 Week Low
- EWTX $10.60
- PD $13.70
- 52 Week High
- EWTX $38.12
- PD $21.98
- Technical
- Relative Strength Index (RSI)
- EWTX 49.70
- PD 42.98
- Support Level
- EWTX $14.85
- PD $16.14
- Resistance Level
- EWTX $15.84
- PD $16.75
- Average True Range (ATR)
- EWTX 1.08
- PD 0.47
- MACD
- EWTX -0.06
- PD -0.07
- Stochastic Oscillator
- EWTX 31.42
- PD 13.00
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.